Phase I/II study of gemcitabine (GEM) and concomitant radiotherapy (RT) in locally advanced carcinoma of the cervix (LACC)

Boualga, K.; Aksil, N.; Ayad, M.; Hasnaoui, N.; Moussaoui, Driss

doi:10.1200/jco.2005.23.16_suppl.5142

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a median follow-up of 11 months (range, 6–14 months), all patients are alive, one with pelvic and another with systemic disease. The authors suggest that ureteral obstruction causing any degree of renal insufficiency should not be a contraindication for receiving chemoradiation to attempt a cure and that in this setting in which cisplatin is contraindicated; gemcitabine use should be considered [ 97 ].…”

Section: Newer Radiosensitizersmentioning

confidence: 99%

Radiosensitizers in cervical cancer. Cisplatin and beyond

et al. 2006

View full text Add to dashboard Cite

Cervical cancer continues to be a significant health burden worldwide. Globally, the majority of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently used therapeutical modality. Currently, the value of adding cisplatin or cisplatin-based chemotherapy to radiation for treatment of locally advanced cervical cancer is strongly supported by randomized studies and meta-analyses. Nevertheless, despite these significant achievements, therapeutic results are far from optimal; thus, novel therapies need to be assayed. A strategy currently being investigated is the use of newer radiosensitizers alone or in combination with platinum compounds. In the present work, we present preclinical information on known and newer cytotoxic agents as radiosensitizers on cervical cancer models, as well as the clinical information emanating from early phase trials that incorporate them to the cervical cancer management. In addition, we present the perspectives on the combined approach of radiation therapy and molecular target-based drugs with proven radiosensitizing capacity.

show abstract

Section: Newer Radiosensitizersmentioning

confidence: 99%

Radiosensitizers in cervical cancer. Cisplatin and beyond

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The first study to evaluate the efficacy and safety of gemcitabine was conducted by McCormack and Thomas [ 15 ] in CC patients treated with gemcitabine at doses of 50 to 150 mg/m 2 /wk, authors reported adequate tolerance, however, the limiting dose of toxicity was not determined. Boualga et al [ 16 ] evaluated gemcitabine at a dose of 300 to 600 mg/m 2 /wk in CC patients, a low toxicity profile and a complete response rate (RR) of 89% were documented. Pattaranutaporn et al [ 17 ], demonstrated adequate tolerance of gemcitabine at a weekly dose of 300 mg/m 2 with a benefit in PFS of 84%, 1 year OS of 100%, and complete RRs of 89%.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities

et al. 2022

View full text Add to dashboard Cite

The standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival.Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function. Materials and MethodsAn observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function. ResultsSixty-three patients treated with gemcitabine at 300 mg/m 2 weekly and 126 patients treated with CDDP 40 mg/m 2 weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline versus 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (HR 2.42, p=0.012). ConclusionIn LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with CANCER RESEARCH AND TREATMENT (CRT)

show abstract

Chemotherapy/chemoradiation in anal cancer: A systematic review

Lim

Glynne‐Jones

2011

Cancer Treatment Reviews

View full text Add to dashboard Cite

Phase I/II study of gemcitabine (GEM) and concomitant radiotherapy (RT) in locally advanced carcinoma of the cervix (LACC)

Cited by 7 publications

References 0 publications

Radiosensitizers in cervical cancer. Cisplatin and beyond

Radiosensitizers in cervical cancer. Cisplatin and beyond

Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities

Chemotherapy/chemoradiation in anal cancer: A systematic review

Contact Info

Product

Resources

About